Novo buys rights to Chinese weight-loss pill in $2.6bn deal - Financial Times
Financial Times
F
Financial Times
Original Source
Danish pharmaceutical giant Novo Nordisk has acquired the rights to market a Chinese weight-loss drug for $2.6 billion, underscoring intensifying competition in the rapidly expanding global obesity treatment market. The acquisition reflects major pharmaceutical companies' aggressive pursuit of a blockbuster segment that has become one of the industry's most coveted therapeutic areas.
Subscribe to read
* Sign In * Subscribe
Open side navigation menuOpen search bar
SubscribeSign In
Popular Searches
* What is the latest news on the UK economy? * Western support for Ukraine * How will AI be regulated? * UK inflation vs the world * How will the UK economy fare in 2026?
* Home * World
Sections
+ World Home + Middle East war + Global Economy + UK + US + China + Africa + Asia Pacific + Emerging Markets + Europe + War in Ukraine + Americas + Middle East & North Africa
Most Read
+ Anthropic warns of ‘existential risks to humanity’ in IPO prospectus + Germany issues EU budget ultimatum + Trump’s ambassador to Greece causes stir in Romania + Rubio says UK air base incident involved ‘foreign actor’ + What ‘Choosin’ Texas’ tells us about Burnham’s social care obstacles * US
Sections
+ US Home + US Economy + US Companies + US Politics & Policy
Most Read
+ Anthropic warns of ‘existential risks to humanity’ in IPO prospectus + Trump’s ambassador to Greece causes stir in Romania + Rubio says UK air base incident involved ‘foreign actor’ + Bond sell-off deepens and oil rises as Iran-US deal hopes fade + Bond investors become oil traders as Iran war drives yields * Companies
Sections
+ Companies Home + Energy + Financials + Health + Industrials + Media + Professional Services + Retail & Consumer + Tech Sector + Telecoms + Transport
Most Read
+ Anthropic warns of ‘existential risks to humanity’ in IPO prospectus + UniCredit’s Orcel moves to seize control of Commerzbank within months + Nvidia launches record $150bn share buyback + Can ‘brutal’ De Meo transform Gucci owner Kering? + Nvidia turns to insurers to spread the risk of AI build-out * Tech
Sections
+ Tech Home + Artificial intelligence + Semiconductors + Cyber Security + Social Media
Most Read
+ Anthropic warns of ‘existential risks to humanity’ in IPO prospectus + Nvidia launches record $150bn share buyback + Nvidia turns to insurers to spread the risk of AI build-out + AMD to buy Fei-Fei Li’s AI start-up for $8bn + Pope Leo criticises Nvidia’s Jensen Huang over AI safety * Markets
+ Anthropic warns of ‘existential risks to humanity’ in IPO prospectus + Bond sell-off deepens and oil rises as Iran-US deal hopes fade + Bond investors become oil traders as Iran war drives yields + Nvidia launches record $150bn share buyback + AI hyperscalers are transforming debt * Climate * Opinion
Sections
+ Opinion Home + Columnists + The FT View + The Big Read + Lex + Obituaries + Letters
Most Read
+ What ‘Choosin’ Texas’ tells us about Burnham’s social care obstacles + Will desk workers be doomed by AI? + Why Europe’s centre will hold + A TV series shows Britain is woefully unprepared for war + Harry Potter and the British business of international schools * Lex * Work & Careers
Sections
+ Work & Careers Home + Business School Rankings + Business Education + Europe's Start-Up Hubs + Entrepreneurship + Recruitment + Business Books + Business Travel + Working It
Most Read
+ Will desk workers be doomed by AI? + An LA bartenders’ crawl across the city’s best drinking dens + The executives going ‘fractional’, not freelance + ‘Translation and connection are different things’: why languages remain useful at work * Life & Arts
Sections
+ Life & Arts Home + Arts + Books + Food & Drink + FT Magazine + House & Home + Style + Puzzles + Travel + FT Globetrotter
Most Read
+ Pass the popcorn: New York’s film-goers are on the warpath + War — Sienna Miller and Dominic West battle it out in bombastic divorce drama + Ministers abandon plan to make overseas visitors pay for England’s top museums + Novo buys rights to Chinese weight-loss pill in $2.6bn deal + Roll the Calls by Ari Emanuel — agent, provocateur * How To Spend It * Stocks Game
MenuSearch
* Home * World * US * Companies * Tech * Markets * Climate * Opinion * Lex * Work & Careers * Life & Arts * How To Spend It * Stocks Game
Financial Times
SubscribeSign In
Popular Searches
* What is the latest news on the UK economy? * Western support for Ukraine * How will AI be regulated? * UK inflation vs the world * How will the UK economy fare in 2026?
Novo buys rights to Chinese weight-loss pill in $2.6bn deal
Subscribe to unlock this article
Save over 40% on Standard Digital
was $540 now $299 for your first year.
Save now on essential digital access to trusted FT journalism on any device. Savings based on annualised monthly price.
Subscribe for $299
* Global news & analysis * Expert opinion * FT App on Android & iOS * FT Edit app * First FT: the day’s biggest stories * 20+ curated newsletters * Follow topics and set up personalized alerts * FT Videos & Podcasts * 10 monthly gift articles to share
Explore more offers.
Trial
$1 for 4 weeks
Then $75 per month. Complete digital access with exclusive insights and industry deep dives on any device. Cancel anytime during your trial.
Select
* Global news & analysis * Expert opinion * FT App on Android & iOS * FT Edit: Access on iOS and web * FirstFT: the day's biggest stories * 20+ curated newsletters * Follow topics & set alerts with myFT * FT Videos & Podcasts * 20 monthly gift articles to share * Lex: FT's flagship investment column * 15+ Premium newsletters by leading experts * FT Digital Edition: our digitised print edition
Premium Digital
Complete coverage
$75 per month
Complete digital access with exclusive insights and industry deep dives on any device.
Select
* Global news & analysis * Expert opinion * FT App on Android & iOS * FT Edit: Access on iOS and web * FirstFT: the day's biggest stories * 20+ curated newsletters * Follow topics & set alerts with myFT * FT Videos & Podcasts * 20 monthly gift articles to share * Lex: FT's flagship investment column * 15+ Premium newsletters by leading experts * FT Digital Edition: our digitised print edition
Print
Save over 65%
was $409 now $129 for your first year
Save now on our curated print edition delivered Monday - Saturday\* plus our digitised print replica. Savings based on annual price.
Select
* Weekday Print Edition * FT Weekend * FT Digital Edition: our digitised print edition * Global news & analysis * Expert opinion * Special features * Exclusive FT analysis
Check whether you already have free access via your university or organisation.
Terms & Conditions apply
\*Hand delivery availability confirmed when you enter your address.
Explore our full range of subscriptions.
For individuals
Discover all the plans currently available in your country
DigitalPrintPrint + Digital
For multiple readers
Digital access for organisations. Includes exclusive features and content.
FT Professional
!Over one million readers pay to read the Financial TimesFind out why
Useful links
Support
Help CentreContact UsAbout UsAccessibilityCareersSuppliers
Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools
Tools
PortfolioFT AppFT Digital EditionFT EditAlerts HubBusiness School RankingsSubscription ManagerNews feedNewslettersCurrency Converter